OncoMatch/Clinical Trials/NCT06178198
Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma
Is NCT06178198 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
The RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in patients with large hepatocellular carcinoma (greater than 8 cm) who maintain good liver function.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Leukocytes ≥ 2,500/µL and ≤ 12,000/µL; Absolute neutrophil count ≥ 1,500 /mm^3; Hemoglobin ≥ 8.0 g/dL (transfusion allowed); Platelet ≥ 50,000/µL
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
Total bilirubin ≤ 3.0 mg/dL; AST ≤ 200 IU/L (≤ 5X ULN); ALT ≤ 200 IU/L (≤ 5X ULN); ALP ≤ 575 IU/L (≤ 5X ULN); INR ≤ 2.0 for patients not taking anticoagulants; Child-Pugh class A
Patients with no major organ dysfunction according to blood tests performed within one month of study enrollment. 1. Leukocytes ≥ 2,500/µL and ≤ 12,000/µL 2. Absolute neutrophil count ≥ 1,500 /mm^3 3. Hemoglobin ≥ 8.0 g/dL (transfusion allowed to meet this criterion) 4. Total bilirubin ≤ 3.0 mg/dL 5. Platelet ≥ 50,000/µL 6. INR ≤ 2.0 for patients not taking anticoagulants 7. AST ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 8. ALT ≤ 200 IU/L (i.e., ≤ 5X upper normal limit) 9. ALP ≤ 575 IU/L (i.e., ≤ 5X upper normal limit) 10. Creatinine ≤ 2.0 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06178198 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages